Login to Your Account

Other News To Note

Wednesday, May 15, 2013

• PharmaMar SA, of Madrid, a subsidiary of Zeltia SA, said it completed enrollment in its Phase IIb study testing PM01183 vs. topotecan in resistant/refractory ovarian cancer. The open-label study is designed to confirm PM01183's activity in that indication.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription